Nicolás Miguel Fissolo I am biochemist and PhD in human biology. Since 2008 I work as a researcher at the clinical neuroimmunology - Multiple Sclerosis Center of Catalonia (Cemcat) research group. My activity is based on the study of multiple sclerosis, mainly in the identification of molecular biomarkers associated to different aspects of the disease. Institutions of which they are part Main researcher Clinical Neuroimmunology Vall Hebron Institut de Recerca Investigador/a postdoctoral Multiple Sclerosis Centre of Catalonia LinkedIn Twitter Orcid Email Nicolás Miguel Fissolo LinkedIn Twitter Orcid Email Institutions of which they are part Main researcher Clinical Neuroimmunology Vall Hebron Institut de Recerca Investigador/a postdoctoral Multiple Sclerosis Centre of Catalonia I am biochemist and PhD in human biology. Since 2008 I work as a researcher at the clinical neuroimmunology - Multiple Sclerosis Center of Catalonia (Cemcat) research group. My activity is based on the study of multiple sclerosis, mainly in the identification of molecular biomarkers associated to different aspects of the disease.
I graduated as a biochemist in 1999 from the University of Córdoba (Argentina). In 2005 I obtained a PhD in human biology from the University of Ulm (Germany) for my work in the DNA vaccine field. Afterwards, I carried out a 3-year postdoctoral stay at the Hertie Institut for Brain Research at the University of Tübingen (Germany) focused on the study of antigenic presentation in multiple sclerosis. In 2008 I joined the research group of the clinical neuroimmunology - Cemcat directed by Dr. Xavier Montalban where I have been working until now. Since 2010 I have been working as principal investigator of several projects focused on the identification of new molecular biomarkers that allow the characterization of the different aspects of the disease, among which are included prognostic biomarkers in the initial phases of the disease, biomarkers of response to treatment, and biomarkers of disease activity.
Projects Immunogenicity: assesing the clinical relevance and risk minimization of antibodies to biopharmaceuticals. IMI Grant Agreement nº 115303 IP: Manuel Comabella Lopez Collaborators: Carmen Tur Gomez, Nicolás Miguel Fissolo Funding agency: The Innovative Medicines Initiative Funding: 464328 Reference: ABIRISK_IMI2010 Duration: 01/03/2012 - 27/02/2018 Vacunas de ADN en Esclerosis Múltiple IP: Nicolás Miguel Fissolo Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 62315 Reference: PI10/01654 Duration: 01/01/2011 - 31/12/2014 Unitat de Neuroimmunologia Clínica (UNiC) IP: Unitat de Neuroimmunologia Clínica (UNiC) Collaborators: Susana Otero Romero, Carlos Nos Llopis, Unitat de Neuroimmunologia Clínica (UNiC), Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Carmen Tur Gomez, Unitat de Neuroimmunologia Clínica (UNiC), Herena Eixarch Ahufinger, Montserrat Moreno Sánchez, Unitat de Neuroimmunologia Clínica (UNiC), M Jesus Arevalo Navines, Carmen Espejo Ruiz, Angela Vidal Jordana, Joaquin Castillo Justribo, Mireia Castillo Juarez, Nicolás Miguel Fissolo , Georgina Arrambide García Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 43680 Reference: 2009 SGR 793 Duration: 01/01/2010 - 30/04/2014 Vacunas de ADN en esclerosis múltiple. IP: Vacunas de ADN en esclerosis múltiple. Collaborators: Nicolás Miguel Fissolo Funding agency: Fundació Institut de Recerca HUVH Funding: 90000 Reference: POST/IR-HUVH/1/2008 Duration: 01/01/2009 - 31/12/2011 Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Next page › Last page »
